VNRX - VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript
2024-05-14 20:24:06 ET
VolitionRx Limited (VNRX)
Q1 2024 Results Conference Call
May 14, 2024 8:30 AM ET
Company Participants
Cameron Reynolds - President, CEO
Terig Hughes - CFO
Andrew Retter - CMO
Gael Forterre - CCO
Louise Batchelor - Chief Marketing & Communications Officer
Conference Call Participants
Bruce Jackson - Benchmark Company
Tim Moore - EF Hutton
Ilya Zubkov - Freedom Broker
Steven Ralston - Zacks
Richard Deutsch - Sutter Securities
Presentation
Operator
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited First Quarter 2024 Earnings Conference Call. During this presentation, all parties are in listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference call is being recorded today, May 14, 2024.
I would now like to turn the conference over to Louise Batchelor, Group's Chief Marketing and Communications Officer. Please go ahead.
Louise Batchelor
Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements may involve risks, uncertainties and assumptions.
Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission.
We do not undertake an obligation to update any forward-looking statements made during the course of this call. We will start the call today with Terig Hughes, our Group Chief Financial Officer, who will cover Volition's financial and operating results for the first quarter of 2024 along with a discussion of recent finance activities and the look ahead. Dr. Andrew Retter, our recently appointed Chief Medical Officer, will provide a commentary about our clinical trial program and then Gael Forterre, our Chief Commercial Officer, will summarize some of the key commercial achievements this quarter with a look ahead to upcoming milestones. Lastly, Cameron Reynolds, our President and Group Chief Executive Officer, will provide a brief wrap up before we open the conference call to a question-and-answer session....
VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript